Ozmen, V. Et Al. 2001. Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome. BREAST CANCER RESEARCH AND TREATMENT , vol.68, no.2 , 147-157.

Ozmen, V., CABIOGLU, N., DOLAY, K., BILIR, A., KECER, M., AYDINER, A., ... MUSLUMANOGLU, M. E.(2001). Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome. BREAST CANCER RESEARCH AND TREATMENT , vol.68, no.2, 147-157.

Ozmen, Vahit Et Al. "Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome," BREAST CANCER RESEARCH AND TREATMENT , vol.68, no.2, 147-157, 2001

Ozmen, Vahit Et Al. "Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome." BREAST CANCER RESEARCH AND TREATMENT , vol.68, no.2, pp.147-157, 2001

Ozmen, V. Et Al. (2001) . "Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome." BREAST CANCER RESEARCH AND TREATMENT , vol.68, no.2, pp.147-157.

@article{article, author={Vahit ÖZMEN Et Al. }, title={Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome}, journal={BREAST CANCER RESEARCH AND TREATMENT}, year=2001, pages={147-157} }